Commentary & Deal Flow

Centrient Holding BV (DSPPHA) EUR600m 144A/Reg S sr sec notes 2-part. TBD (exising B3 1st lien rating is on review for upgrade)/B (--/stable). Via Citi (B&D)/MS jt glocos/ABN AMRO/GS/Jefferies/Muzuho/Rabo/RBC jt books. No reg rights. List ISE. NY law.

   - EUR300m sr sec fixed-rate notes due May 2030 (5y). NC2 (50%,25%,par). IPT: mid-to-high 7s.

  - EUR300m sr sec FRN due May 2030 (5y). NC1 (par). IPT: E+475bp at 98.50-99.00.

Roadshow (small group meetings) 05/12-13 (investor call at 11am UKT 05/12). UOP: refinance its EUR515m 1st lien term loan B due 2027 and EUR83m 2nd lien term loan due 2028. Equity sponsor: Bain. Biz: B2B pharma developer and manufacturer of intermediates, active pharmaceutical ingredients (APIs) and finished dosage forms. HQ: Rotterdam, Netherlands.

Netroadshow link: https://www.netroadshow.com/events/login?show=d42d5062&confId=82536